ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: 1099 • 2016 ACR/ARHP Annual Meeting

    Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis

    Ji Eun Song1, Ji Hye Shin1, Ki Won Moon2, Se Hui Shon1, Ji Soo Park3, Eun Bong Lee3, Yeong Wook Song1,3 and Eun Young Lee3, 1Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, 2Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Republic of Korea, Chuncheon, Korea, The Republic of, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of

    Background/Purpose:  Exosomes are small membrane vesicles (40-150 nm) of endocytic origin secreted by many types of cells and engage in cell-to-cell communication by transferring proteins,…
  • Abstract Number: 2300 • 2016 ACR/ARHP Annual Meeting

    Tophaceous Gout and the Risk of Mortality: A General Population-Based Study

    Hyon K. Choi1, Leo Lu2, Sharan K. Rai3,4 and Yuqing Zhang5, 1Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA

    Tophaceous Gout and the Risk of Mortality: A General Population-Based Study Background/Purpose: A recent study based on data from a gout specialty clinic (N=706) found…
  • Abstract Number: 207 • 2016 ACR/ARHP Annual Meeting

    Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout

    Michael A. Becker1, Robert T. Keenan2, Puja Khanna3, Raymond Malamet4, Kathleen Bos4, Jingyi Li4, Jia Hu5 and William White6, 1University of Chicago, Chicago, IL, 2Rheumatology, Duke University, Durham, NC, 3Rheumatology, University of Michigan, Ann Arbor, MI, 4AstraZeneca Pharmaceuticals, Wilmington, DE, 5Ardea Biosciences, Inc., San Diego, CA, 6University of Connecticut School of Medicine, Farmington, CT

    Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment…
  • Abstract Number: 1242 • 2016 ACR/ARHP Annual Meeting

    Rate of Hospitalization for Heart Failure Is Lower in Patients with Controlled Gout Versus Uncontrolled Gout

    Robert Morlock1, Pierre Chevalier2 and Alyssa B Klein3, 1Ardea Biosciences, Inc., San Diego, CA, 2IMS Health, New York, NY, 3AstraZeneca, Gaithersburg, MD

    Background/Purpose: Hyperuricemia is associated with worsened outcomes in heart failure (HF) patients. However, little is known regarding the association between gout and HF itself. This…
  • Abstract Number: 2303 • 2016 ACR/ARHP Annual Meeting

    Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011

    Sharan K. Rai1,2, J. Antonio Avina-Zubieta2,3, Natalie McCormick2,4, Mary A. De Vera2,5, Diane Lacaille2,6, Eric C. Sayre2 and Hyon K. Choi7,8, 1Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Canada, Richmond, BC, Canada, 3Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 4Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 5Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 6Medicine, University of British Columbia, Vancouver, BC, Canada, 7Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 8Arthritis Research Canada, Vancouver, BC, Canada

    Background/Purpose: Gout and rheumatoid arthritis (RA) are the two most common forms of inflammatory arthritis worldwide. As hospitalizations for both conditions lead to substantial health…
  • Abstract Number: 208 • 2016 ACR/ARHP Annual Meeting

    Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout

    Kenneth Saag1, Michael A. Becker2, Chris Storgard3, Maple Fung3, Jia Hu3 and Thomas Bardin4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Chicago, Chicago, IL, 3Ardea Biosciences, Inc., San Diego, CA, 4Hôpital Lariboisière, Paris, France

    Background/Purpose: Two replicate, randomized, core Phase III trials (CLEAR 1 & 2) reported significantly more subjects treated with lesinurad 200 mg (LESU200) or 400 mg…
  • Abstract Number: 2022 • 2016 ACR/ARHP Annual Meeting

    Developing a Gout Needs Assessment Incorporating Patient Perspective on  Self-Management, Self-Efficacy and Disease Specific Knowledge, to Inform a Patient Education Initiative

    Adam Rifaat1, Adena Batterman2, Roberta Horton2 and Theodore R. Fields1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Social Work Programs, Hospital for Special Surgery, New York, NY

    Background/Purpose: Gout is the most common inflammatory arthritis in adults, with great impact on quality of life. Despite excellent therapeutic options, outcomes remain suboptimal. Research supports…
  • Abstract Number: 2305 • 2016 ACR/ARHP Annual Meeting

    Mapping the Topography of Gout Flares: Solutions for Flare Reporting in Gout Clinical Trials

    Novell Teoh1, Gregory Gamble2, Anne Horne2, William J. Taylor3, Kate Palmano4 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Otago, Wellington, New Zealand, 4Consultant Scientist, Waikato, New Zealand

    Background/Purpose : Recurrent flares of inflammatory arthritis are the central clinical feature of gout.  However, methods of gout flare reporting in research settings are inconsistent…
  • Abstract Number: 209 • 2016 ACR/ARHP Annual Meeting

    Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout

    Thomas Bardin1, Nicola Dalbeth2, Robert Terkeltaub3, Chris Storgard4, Maple Fung4, Jia Hu4 and Fernando Perez-Ruiz5, 1Hôpital Lariboisière, Paris, France, 2University of Auckland, Auckland, New Zealand, 3Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, 4Ardea Biosciences, Inc., San Diego, CA, 5Hospital de Cruces and Biocruces Health Research Institute, Vizcaya, Spain

    Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…
  • Abstract Number: 2266 • 2016 ACR/ARHP Annual Meeting

    A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout

    Ronald Berenson1, Maura-Ann Matthews1, Wayne Wallis2, Raj Dua1, Margaret Moore1, Robert Terkeltaub3 and Christopher Clegg1,4, 1Aequus BioPharma, Inc., Seattle, WA, 2Dyad Life Sciences, LLC, Seattle, WA, 3Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, 4TRIA Bioscience, Seattle, WA

    Background/Purpose: The melanocortins (MCs) are endogenous peptides (including ACTH, α-MSH and γ-MSH), which bind 5 G protein-coupled receptors (MCRs 1 through 5) with varying affinity.…
  • Abstract Number: 3071 • 2016 ACR/ARHP Annual Meeting

    Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response

    Marwa Qadri1, Tannin Schmidt2, Khaled Elsaid3 and Gregory Jay4, 1Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, 2Kinesiology and Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, 3Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA, 4Emergency Medicine, Brown University, Providence, RI

    Background/Purpose:   Gout is an inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in synovial joints. MSU crystals interact with resident macrophages that…
  • Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting

    Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response

    Brian F. Mandell1, Michael Weisman2, Anthony Yeo3 and Peter E. Lipsky4, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, 3Horizon Pharma, Lake Forest, IL, 4AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…
  • Abstract Number: 2268 • 2016 ACR/ARHP Annual Meeting

    Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity

    Xihua Cao1, Jeffrey N. Miner2, Robert Terkeltaub3,4 and Ru Liu-Bryan1,4, 1VA Medical Center, San Diego, CA, 2Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, 3Rheumatology, VA Medical Center, San Diego, CA, 4Medicine-Rheumatology, University of California, San Diego, La Jolla, CA

    Background/Purpose: High dietary content of fructose (in table sugar, sweetened sodas, energy beverages, and fruit juices) is a substantial risk factor for both hyperuricemia and…
  • Abstract Number: 3074 • 2016 ACR/ARHP Annual Meeting

    Population-Specific Association Between ABCG2 Variants and Tophaceous Disease in People with Gout

    Wendy He1, Amanda Phipps-Green2, Lisa K. Stamp3, Tony R. Merriman4 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Dunedin, New Zealand, 3University of Otago, Christchurch, New Zealand, 4Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

    Background/Purpose: Tophi contribute to musculoskeletal disability, joint damage and poor health-related quality of life in people with gout. The aim of this study was to…
  • Abstract Number: 213 • 2016 ACR/ARHP Annual Meeting

    Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices

    Amar Majjhoo1, Kome Okposo2 and Michael Zdanis3, 1Shores Rheumatology, St. Clair Shores, MI, 2Horizon Pharma, Lake Forest, IL, 3Cetus Group, LLC, Towson, MD

    Background/Purpose: Corticosteroids are commonly utilized, along with other agents in clinical practice for pre-infusion prophylaxis prior to the administration of therapeutic biologic proteins. Two steroids,…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 45
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology